1. Home
  2. GRFS vs LEGN Comparison

GRFS vs LEGN Comparison

Compare GRFS & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$8.67

Market Cap

6.5B

Sector

Health Care

ML Signal

HOLD

Logo Legend Biotech Corporation

LEGN

Legend Biotech Corporation

HOLD

Current Price

$18.00

Market Cap

5.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRFS
LEGN
Founded
1940
2014
Country
Spain
United States
Employees
23800
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5B
5.9B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
GRFS
LEGN
Price
$8.67
$18.00
Analyst Decision
Hold
Buy
Analyst Count
2
14
Target Price
$10.15
$63.46
AVG Volume (30 Days)
560.8K
2.1M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
1.57%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$5.47
$67.72
Revenue Next Year
$4.92
$43.82
P/E Ratio
$18.67
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.19
$16.24
52 Week High
$11.14
$45.30

Technical Indicators

Market Signals
Indicator
GRFS
LEGN
Relative Strength Index (RSI) 38.13 41.00
Support Level $8.24 $16.24
Resistance Level $9.11 $23.68
Average True Range (ATR) 0.28 0.88
MACD -0.07 0.18
Stochastic Oscillator 25.50 8.09

Price Performance

Historical Comparison
GRFS
LEGN

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Share on Social Networks: